Breast Cancer ER PR HER2 Ki67 Test: Comprehensive Biomarker Analysis for Personalized Treatment
Understanding the Breast Cancer Biomarker Test
The Breast Cancer ER PR HER2 Ki67 Test represents a cornerstone in modern breast cancer diagnostics, providing essential molecular information that guides personalized treatment decisions. This comprehensive immunohistochemistry panel analyzes four critical biomarkers that determine breast cancer subtype and predict response to specific therapies. By evaluating these molecular characteristics, oncologists can develop targeted treatment strategies that maximize effectiveness while minimizing unnecessary side effects.
What This Advanced Test Measures
This sophisticated diagnostic panel evaluates four key biomarkers that define breast cancer biology:
- Estrogen Receptors (ER): Determines if cancer cells have estrogen receptors, indicating potential response to hormone-blocking therapies
- Progesterone Receptors (PR): Assesses progesterone receptor status, providing additional information about hormone sensitivity
- HER2 Protein: Evaluates human epidermal growth factor receptor 2 expression, identifying candidates for targeted HER2 therapies
- Ki67 Proliferation Index: Measures the percentage of actively dividing cancer cells, indicating tumor aggressiveness
Who Should Consider This Comprehensive Testing?
This advanced biomarker testing is recommended for individuals with:
- Newly diagnosed breast cancer requiring treatment planning
- Recurrent breast cancer needing updated biomarker assessment
- Metastatic breast cancer requiring targeted therapy options
- Invasive breast carcinoma of any stage
- Patients considering neoadjuvant (pre-surgical) therapy
- Those with ambiguous initial pathology results
Clinical Indications and Symptoms
Patients presenting with breast abnormalities, suspicious mammogram findings, palpable breast masses, or confirmed breast cancer diagnosis should discuss this comprehensive testing with their healthcare provider. Early biomarker assessment ensures appropriate treatment selection from the beginning of the cancer journey.
Significant Benefits of Comprehensive Biomarker Testing
Undergoing the Breast Cancer ER PR HER2 Ki67 Test provides multiple advantages:
- Personalized Treatment Planning: Enables selection of therapies specifically matched to your cancer’s molecular profile
- Avoidance of Ineffective Treatments: Identifies therapies unlikely to benefit your specific cancer type
- Improved Survival Outcomes: Targeted therapies based on biomarker status have demonstrated superior results
- Reduced Treatment Side Effects: Minimizes exposure to unnecessary chemotherapy or ineffective medications
- Prognostic Information: Provides insight into cancer aggressiveness and potential behavior
- Clinical Trial Eligibility: May qualify patients for novel targeted therapy trials
Understanding Your Test Results
Your comprehensive biomarker results will provide critical information for treatment decisions:
Estrogen and Progesterone Receptor Status
Positive Results: Indicate hormone receptor-positive cancer, typically responsive to endocrine therapies like tamoxifen or aromatase inhibitors. These cancers generally have better prognosis and multiple treatment options.
Negative Results: Suggest hormone receptor-negative cancer, which won’t respond to hormone-blocking treatments but may benefit from chemotherapy or other targeted approaches.
HER2 Status Interpretation
HER2-Positive: Identifies cancers that may respond exceptionally well to HER2-targeted therapies like trastuzumab (Herceptin), pertuzumab, or ado-trastuzumab emtansine.
HER2-Negative: Indicates standard HER2-targeted therapies won’t be effective, guiding consideration of alternative treatment strategies.
Ki67 Proliferation Index
High Ki67 (>20%): Suggests more aggressive cancer behavior, often indicating benefit from chemotherapy in addition to other treatments.
Low Ki67 (≤20%): Typically indicates less aggressive cancer that may not require intensive chemotherapy regimens.
Test Information and Pricing
| Test Component | Details |
|---|---|
| Test Name | Breast Cancer ER PR HER2 Ki67 Test |
| Regular Price | $500 USD |
| Discount Price | $350 USD |
| Turnaround Time | 10 days |
| Sample Type | Tumor tissue in 10% formal-saline OR formalin fixed paraffin embedded block |
| Methodology | Immunohistochemistry with pathologist review |
Sample Requirements and Preparation
For optimal testing, please provide tumor tissue samples properly preserved in 10% formal-saline solution or as formalin-fixed paraffin-embedded blocks. Ship samples at room temperature and include essential documentation: a copy of the histopathology report, complete clinical history, and clear indication of the biopsy site. These requirements ensure accurate biomarker assessment and reliable results.
Nationwide Accessibility and Convenience
We maintain comprehensive testing facilities across the United States, with branches conveniently located in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and numerous other cities. Our nationwide network ensures timely sample processing and result delivery regardless of your location.
Take Control of Your Breast Cancer Journey
Comprehensive biomarker testing represents a critical step in developing an effective, personalized treatment strategy for breast cancer. By understanding your cancer’s specific molecular characteristics, you and your healthcare team can make informed decisions about the most appropriate therapies for your unique situation.
Ready to Schedule Your Test?
Don’t leave your treatment decisions to chance. Contact our specialized oncology testing team today to schedule your Breast Cancer ER PR HER2 Ki67 Test and take the first step toward personalized cancer care.
Call or WhatsApp: +1(267) 388-9828
Our experienced genetic counselors and oncology specialists are available to answer your questions, explain the testing process, and help you understand how comprehensive biomarker analysis can guide your treatment journey.
